Author

Praneeth Jarugula

Institution: Bristol-Myers Squibb (United States)

Observed institutions: University of Maryland, Baltimore, Bristol-Myers Squibb (United States)

ORCID: 0000-0002-6922-2483

Observed ORCID: 0000-0002-6922-2483

OpenAlex ID: A5026090071

Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease

2023 · R. Mark Payne, Kristin M. Burns, et al. · Journal of the American College of Cardiology · 56

Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections

2020 · Alison L. Blackman, Praneeth Jarugula, et al. · Antimicrobial Agents and Chemotherapy · 40

Optimizing Vancomycin Dosing and Monitoring in Neonates and Infants Using Population Pharmacokinetic Modeling

2022 · Praneeth Jarugula, Ayse Akcan-Arikan, et al. · Antimicrobial Agents and Chemotherapy · 20

Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy

2025 · Neal K. Lakdawala, Ray E. Hershberger, et al. · Journal of the American College of Cardiology · 9

Understanding the Role of Pharmacometrics‐Based Clinical Decision Support Systems in Pediatric Patient Management: A Case Study Using Lyv Software

2021 · Praneeth Jarugula, Sarah Scott, et al. · The Journal of Clinical Pharmacology · 8

Absolute oral bioavailability of milvexian spray‐dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach

2024 · Praneeth Jarugula, Sharif Soleman, et al. · Clinical and Translational Science · 6

Abstract PS17-08: Population pharmacokinetic and exposure-response modeling of the oral selective estrogen receptor degrader, rintodestrant (G1T48), in patients with ER+/HER2- advanced breast cancer

2021 · Andrew P Beelen, Chao Li, et al. · Cancer Research · 4

Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart Disease

2025 · Antoinette Ajavon‐Hartmann, Praneeth Jarugula, et al. · Clinical Pharmacology & Therapeutics · 3

Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase

2025 · Praneeth Jarugula, Toni Ajavon‐Hartmann, et al. · Clinical Pharmacology & Therapeutics · 3

Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies

2026 · Ran Reshef, Jacques Azzi, et al. · Transplantation and Cellular Therapy · 2

OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial

2026 · Dinesh Khanna, David S Korman, et al.

Pharmacometric analyses supporting apixaban doses in neonates with venous thromboembolism

2025 · Puneet Gaitonde, Praneeth Jarugula, et al. · Blood

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction

2025 · Praneeth Jarugula, Sanchita Basu, et al.

450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections

2019 · Alison L Blackman, Praneeth Jarugula, et al. · Open Forum Infectious Diseases

Works count: 14

Citation count: 150

H-index: 6

I10-index: 3